A bad day for Molecular Partners
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
Outside big pharma, life remains tough for listed developers
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
Veru gets a big Covid boost
But full data will be needed to confirm that sabizabulin is a real contender.
UK Recovery trial confirms Covid benefit for Olumiant
But, in the US, the NIH-backed Activ-2 trial shuts down an arm studying an SAB antibody, and tells Synairgen to hold tight.
Rare disease and neurology takeouts tick higher
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
A bad day for Molecular Partners
Setbacks hit two of the Swiss biotech’s clinical-stage darpin projects in a single day.
First-quarter biotech risers work hard for the win
Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.
Outside big pharma, life remains tough for listed developers
A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.
Veru gets a big Covid boost
But full data will be needed to confirm that sabizabulin is a real contender.
UK Recovery trial confirms Covid benefit for Olumiant
But, in the US, the NIH-backed Activ-2 trial shuts down an arm studying an SAB antibody, and tells Synairgen to hold tight.
Rare disease and neurology takeouts tick higher
Biopharma's growing appetite for higher-risk areas prompts a shift in dealmaking strategies, our latest deep dive into M&A data finds.
